Nanotechnology Drug Delivery Market 2015 - Industry Perspective and Comprehensive Analysis 2023

Nanotechnology drug delivery is a growing field and is witnessing increasing acceptance in health care applications. Nanotechnology drug delivery is widely used in the health care industry in applications such as neurology, anti-infective, cardiovascular disorders, and others. One important and active application area of nanotechnology drug delivery systems is to transport drugs to the final location of therapeutic intervention within the body. The nanotechnology drug delivery market is witnessing rapid growth due to increase in research and development activities in nanotechnology to develop novel nano-medicine. According to Eurostat comprehensive data, the nano-medicine industry in the EU includes 97 startups, 64 SMEs, and 38 large pharmaceutical or medical device companies. Furthermore, technological advancements and rising interest of key companies to invest in nanotechnology boost market growth. For instance, in 2011–2012, Pfizer, Inc., Amgen, Inc., and AstraZeneca signed agreements to collaborate with BIND Therapeutics to develop nano-medicines. These initiatives are expected to fuel the growth of the nanotechnology drug delivery market in the near future. However, stringent regulatory scenario and high development cost of medicines through nanotechnology are likely to hamper market growth during the forecast period. The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.

This 120 page report gives readers a comprehensive overview of the nanotechnology drug delivery market. Browse through 12 data tables and 45 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nanotechnology-drug-delivery.html

Based on technology, the global nanotechnology drug delivery market has been segmented into nanocrystals, nanoparticles, liposomes, micelles, nanotubes, and others. The nanoparticles segment dominated the global nanotechnology drug delivery market in 2014. The segment dominated the market as key nanoparticles such as dendrimers, gold nanoparticles, and fullerenes are used in pharmaceutical drug delivery. The nanotubes segment is expected to expand at the highest CAGR during the forecast period from 2015 to 2023.

Based on application, the market has been segmented into neurology, oncology, cardiovascular/physiology, anti-inflammatory/immunology, anti-infective, and others. Anti-infective was the largest application segment of the nanotechnology drug delivery market due to rising prevalence of community-based and hospital-based infections.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving nanotechnology drug delivery market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1822

Geographically, North America dominated the global nanotechnology drug delivery market in 2014. Rising incidence of chronic diseases such as cancer and diabetes in the region fueled the growth of the nanotechnology drug delivery market in North America. Europe accounted for the second largest share of the market in 2014 owing to the favorable growth conditions for pharmaceutical and biotechnology manufacturers due to affordability for branded nanotechnology products by consumers. However, the market in Latin America is estimated to expand at the highest CAGR during the forecast period. High market growth in this region is due to increasing interest of leading companies such as Novartis and Johnson & Johnson to establish their presence in countries in Latin America such as Brazil and Mexico.

Key players having presence in the global nanotechnology drug delivery market are AbbVie, Inc., Amgen, Inc., Celgene Corporation, Johnson & Johnson, Merck & Co., Inc., and Novartis International AG, among others.

Nanotechnology Drug Delivery Market 2015 - Industry Perspective and Comprehensive Analysis 2023

In 2014, the three leading players in the global nanotechnology drug delivery market - Amgen, Inc., Teva Pharmaceuticals, and Novartis - had held a collective share of 26.3%. This extremely fragmented market comprises of a large number of players that are already globally prominent while still having close to half its size dedicated to regional and local players.
As per the findings revealed by Transparency Market Research in its report, the degree of competition in the global nanotechnology drug delivery market is extremely high, owing to the large number of existing players in it. The demand for nanotechnology drug delivery systems is exceptionally high and is increasing at a fast pace. Additionally, the scope of invention and innovation is still very high, allowing players to find success in even niche roles.
This 120 page report gives readers a comprehensive overview of the nanotechnology drug delivery market. Browse through 12 data tables and 45 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nanotechnology-drug-delivery.html
The global market for nanotechnology drug delivery is expected to continue its bold CAGR of 12.5% within a forecast period from 2015 to 2023, in terms of revenue. This revenue is expected to reach US$51,969.7 mn by the end of 2016 and US$118,527.2 mn by the end of 2023. In terms of technologies, the global nanotechnology drug delivery market has been dominated by the segment of nanoparticles. By the end of 2023, the applications of nanoparticles in drug delivery are expected to generate US$33,543.2 mn in revenue.
North America Retains Dominant Usage and Scope of Drug Delivery Methods
North America has consistently held the leading spot in the global nanotechnology drug delivery market in terms of value. By the end of 2023, North America is expected to hold 44,450.5 mn of the revenue generated in the global nanotechnology drug delivery market. The primary reason for this is the medical and healthcare advancements that this region had already possessed over others. Close to 80% of all research and development efforts in the global biopharmaceutical industry take place within the U.S., which is also the leading regional user of nanotechnology in healthcare and specifically, drug delivery.
On the other hand, the emerging Asia Pacific region and its booming healthcare sector has put forth its stronger foot. Key countries in this region are exhibiting a phenomenal rate of growth in the healthcare and medical devices industries. This rapid economic growth rate, coupled with a growing expenditure on healthcare by patients, and the steadily increasing demand for the treatment of chronic diseases, is what may set Asia Pacific on track to challenge the greater shares held by North America and Europe.
Nanotechnology Drug Delivery Finds Application Scope Against Multiple Diseases
“The global nanotechnology drug delivery market has one highly sought-after concept working in its favor: the efficacy with which drug delivery can be achieve using these techniques has allowed for the development of incredibly potent drugs that can be used to combat a lot of the top priority diseases of today. The list includes a number of infectious diseases, genetic disorders, pulmonary diseases, cardiovascular diseases, and several forms of cancer,” states a TMR analyst.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving nanotechnology drug delivery market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1822
The introduction of nanotechnology drug delivery has revolutionized the pharmaceutical industry on a much larger scale. The traditional pharmaceutical design of LADME has now been transformed to include other processes such as circulation time, targeting, and triggered activation.
Venture Funds Scarcity Slows Nanotechnology Drug Delivery Market Down
There are quite a few factors responsible for restraining the growth rate of the global nanotechnology drug delivery market. One of the key restraints is the relative lack of venture funds. There are significant investments being made into the market for research and development efforts. However, in the broader picture, the market is still in a very early and formative stage and is in need of deeper investment pools to progress at a satisfactory rate. Other problems include the long waiting time of approval processes and the general lack of accuracy regarding what fields are a part of nano-medicine.
The information presented in this review is based on a Transparency Market Research report, titled, “Nanotechnology Drug Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”